Paeoniflorin (Monoterpene Glycoside)

Paeoniflorin is a monoterpene glycoside extracted from peony root that demonstrates anti-inflammatory and cardiovascular protective effects. This bioactive compound works primarily by inhibiting NF-κB activation and reducing pro-inflammatory cytokines like TNF-α and IL-6.

Origin & History

Paeoniflorin is a monoterpene glycoside primarily extracted from the root of Paeonia lactiflora Pall. (peony), a plant used in traditional Chinese medicine for over 1000 years. It is isolated as a key component of total glycosides of paeony (TGP), often alongside related compounds like albiflorin.

Historical & Cultural Context

Paeoniflorin comes from Paeonia lactiflora root (paeony), used in traditional Chinese medicine for over 1000 years to treat pain, inflammation, immune disorders, and gynecological issues. Total glycosides of paeony (TGP), rich in paeoniflorin, are currently used in over 1000 Chinese hospitals for rheumatoid arthritis and systemic lupus erythematosus.

Health Benefits

• Anti-inflammatory effects: Reduces TNF-α, IL-6, and NF-κB activation (animal studies only)
• Arthritis support: Inhibited synoviocyte proliferation and cytokines in adjuvant arthritis rats at 10-20 mg/kg/day (preclinical evidence)
• Cardiovascular protection: Reduced lipids (TC, TG, LDL-C) and inflammation in atherosclerosis rodent models at 10-60 mg/kg (animal studies)
• Sepsis protection: Reduced lethality and inflammatory markers in rat sepsis models (intravenous administration, preclinical)
• Immune modulation: Downregulates HMGB1-RAGE/TLR signaling pathways (cell and animal studies only)

How It Works

Paeoniflorin exerts its effects by suppressing nuclear factor-κB (NF-κB) activation, which reduces the expression of inflammatory mediators including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). The compound also modulates lipid metabolism pathways, leading to decreased total cholesterol, triglycerides, and LDL cholesterol levels. Additionally, paeoniflorin inhibits synoviocyte proliferation through cytokine regulation in inflammatory joint conditions.

Scientific Research

Current evidence for paeoniflorin is limited entirely to preclinical animal and cell studies, with no human clinical trials, RCTs, or meta-analyses available. Key preclinical studies include rat models of sepsis showing reduced inflammatory markers, and adjuvant arthritis models demonstrating anti-inflammatory effects at oral doses of 10-20 mg/kg/day (PMID: 17588133).

Clinical Summary

Current evidence for paeoniflorin comes primarily from animal studies and preclinical research. In adjuvant arthritis rat models, doses of 10-20 mg/kg/day demonstrated significant inhibition of synoviocyte proliferation and inflammatory cytokine production. Cardiovascular studies in animal models showed measurable reductions in total cholesterol, triglycerides, and LDL cholesterol levels. Human clinical trials are limited, making the translation of these preclinical benefits to human populations uncertain.

Nutritional Profile

Paeoniflorin is a purified monoterpene glycoside compound, not a whole food ingredient, and therefore contains no macronutrients (protein, fat, carbohydrates), dietary fiber, vitamins, or minerals in any meaningful nutritional sense. As an isolated bioactive compound, its profile is defined entirely by its chemical and pharmacokinetic properties: Molecular formula C23H28O11, molecular weight 480.45 g/mol. It is the principal active constituent of Paeonia lactiflora (white peony root), comprising approximately 1.1–5.5% of dried root weight by mass. Structurally, it consists of a pinane-type monoterpene aglycone (paeoniflorigenone core) linked to a glucose moiety via a beta-glycosidic bond. Bioavailability is notably poor when taken orally: absolute oral bioavailability in rodent studies is reported at approximately 3.5–6.9%, attributed to low intestinal permeability (classified as a BCS Class III/IV compound), P-glycoprotein efflux, and first-pass hepatic metabolism. Gut microbiota partially hydrolyze the glycoside bond, releasing the aglycone paeoniflorigenin, which may contribute to systemic effects. Peak plasma concentration (Tmax) is reached within 0.5–2 hours post-oral administration in animal models. Co-administration with absorption enhancers or liposomal formulations has been shown in preclinical studies to increase bioavailability by 2–4 fold. No caloric value is applicable at physiologically relevant doses (typically 50–200 mg in human-equivalent estimates).

Preparation & Dosage

No human dosage studies exist. Animal studies used oral doses of 10-20 mg/kg/day for arthritis (18-20 days) and 10-60 mg/kg/day for atherosclerosis (6-18 weeks). Human pharmacokinetic data shows a short half-life of 1.8-1.9 hours after IV administration. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Albiflorin, Total Glycosides of Paeony (TGP), Curcumin, Boswellia, Quercetin

Safety & Interactions

Paeoniflorin appears well-tolerated in animal studies at therapeutic doses, but comprehensive human safety data is lacking. The compound may interact with anticoagulant medications due to potential effects on blood coagulation pathways. Pregnant and breastfeeding women should avoid paeoniflorin supplements due to insufficient safety data. Individuals with bleeding disorders or those taking blood-thinning medications should consult healthcare providers before use.